

Special Issue

New Biomarkers for Diagnosis and Therapy in Civilization Diseases

Message from the Guest Editors

The cell surface markers has become an indispensable tool for diagnosing hematological malignancies and monitoring minimal residual diseases. The increase of average age highlights neurodegenerative pathologies and the presence of inflammation, representing new challenges in therapies and biomarker research fields. The applications of gene chips and microarray technology to simultaneously assess multiple molecular markers with Next-Generation Sequencing (NGS), used to sequence entire genomes or constrained to specific areas of interest, are simple and cheaper. Bioluminex, Planar Array Assay and other new assays open new scenarios for autoimmune diseases. The use of different matrixes, such as as saliva, cerebrospinal fluid, tears and synovial fluids, will be evaluated. The aim of this Special Issue is to invite original research articles or reviews presenting and discussing the advancement of biomarkers research and innovative therapies involved in cancer, autoimmune diseases and neurodegenerative diseases, with a special interest in the use of biological drugs in these pathologies and advances in genetics, in innovative assays and in molecular diagnostics.

Guest Editors

Dr. Umberto Basile

Head of Clinical Pathology Unit, Hospital "Santa Maria Goretti" ASL Latina, Latina, Italy


Prof. Dr. Silvia Angeletti

1. Operative Research Unit of Laboratory, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Rome, Italy

2. Research Unit of Clinical Laboratory Science, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128 Rome, Italy

Deadline for manuscript submissions

closed (10 November 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/153293

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).